To investigate the therapeutic potential, safety, and translational feasibility of recombinant human IL-37 and IL-38 (rhIL-37/38) in RA, we propose a comprehensive two-stage experimental framework integrating in vitro, in vivo, and ex vivo approaches. The gene discussed is IL1F10; the disease is rheumatoid arthritis.